Endocrine and Metabolic Disorders: Clinical Lab Testing Manual, Fourth Edition

Endocrine and Metabolic Disorders: Clinical Lab Testing Manual, Fourth Edition

Volumn , Issue , 2009, Pages 1-575

  Dons, Robert F ^a   Wians, Frank H ^b,c,d,e  

^a The Southwestern Medical Center ^*  (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c National Academy of Clinical Biochemistry   (United States)

^d American Society of Clinical Pathologists   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85073887580     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9781420079364     Document Type: Book

References (78)

1. Bayer MF. Performance criteria for appropriate characterization of “(highly) sensitive” thyrotropin assays. Clin Chem 1987; 33:630–1.
2. Fraser CG. Biological Variation: From Principles to Practice. 2001. AACC Press, 151 pp.
3. Fraser CG, Williams P. Short-term biological variation of plasma analytes in renal disease. Clin Chem 1983; 29:508–10.
4. Lamb CR. Statistical briefing: estimating the probability of disease. Vet Radiol Ultrasound 2008; 49:109–10.
5. Maes M, Mommen K, Hendrickx D, Peeters D, D’Hondt P, Ranjan R, De Meyer F, Scharpe S. Components of biological variation, including seasonality, in blood concentrations of TSH, TT3, FT4, PRL, cortisol and testosterone in healthy volunteers. Clin Endocrinol 1997; 46:587–98.
6. Obuchowski NA, Lieber ML, Wians FH Jr. ROC curves in clinical chemistry: uses, misuses, and possible solutions. Clin Chem 2004; 50:1118–25.
7. Wians FH Jr, Baskin LB. The use of clinical laboratory tests in diagnostic decision-making. In: Handbook of Clinical Pathology. 2000. ASCP Press, pp. 9–24.
8. Wians FH Jr, Cheli CD, Balko JA, Bruzek DJ, Chan DW, Sokoll LJ. Evaluation of the clinical performance of equimolar- and skewed-response total prostate-specific antigen assays versus complexed and free PSA assays and their ratios in discriminating between benign prostatic hyperplasia and prostate cancer. Clin Chim Acta 2002a; 326:81–95.
9. Wians FH Jr, Koch DD, Haara A. Quality control/quality assurance. In: Clinical Chemistry, Lewandrowski K (Ed). 2000b. Lippincott, Williams & Wilkins, pp. 81–106.
10. Wu AHB, Smith A, Wieczorek S, Mather JF, Duncan B, White CM, McGill C, Katten D, Heller G. Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol 2003; 92:628–31.
11. Chi DD, Toshima K, Donis-Keller H, Wells SA. Predictive testing for multiple endocrine neoplasia type 2A (MEN 2A) based on the detection of mutations in the RET protooncogene. Surgery 1994; 116:124–33.
12. Goodfellow PJ. Inherited cancers associated with the RET proto-oncogene. Curr Opin Genet Dev 1994; 4:446–52.
13. Ledger GA, Khosla S, Lindor NM, Thibodeau SN, Gharib H. Genetic testing in the diagnosis and management of multiple endocrine neoplasia type II. Ann Intern Med 1995; 122:118–24.
14. Lips CJ, Landsvater RM, Hoppener JW, Geerdink RA, Blijham G, van Veen JM, van Gils AP, de Wit MJ, Zewald RA, Berends MJ et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 1994; 331:828–35.
15. van Heurn LW, Schaap C, Sie G, Haagen AA, Gerver WJ, Freling G, van Amstel HK, Heineman E. Predictive DNA testing for multiple endocrine neoplasia 2: a therapeutic challenge of prophylactic thyroidectomy in very young children. J Pediatr Surg 1999; 34:568–71.
16. Wells SA, Donis-Keller H. Current perspectives on the diagnosis and management of patients with multiple endocrine neoplasia type 2 syndromes. Endocrinol Metab Clin North Am 1994; 23:215–28.
17. Marshall AH, Jones NS, Robertson IJ. CSF rhinorrhoea: the place of endoscopic sinus surgery. Br J Neurosurg 2001; 15:8–12.
18. Galvin P, Ward G, Walters J, Pestell R, Koschmann M, Vaag A, Martin I, Best JD, Alford F. A simple method for quantitation of insulin sensitivity and insulin release from an intravenous glucose tolerance test. Diabet Med 1992; 9:921–8.
19. Haffner SM, D’Agostino R, Festa A, Bergman RN, Mykkanen L, Karter A, Saad MF, Wagenknecht LE. Low insulin sensitivity (S(i) = 0) in diabetic and nondiabetic subjects in the insulin resistance atherosclerosis study: is it associated with components of the metabolic syndrome and nontraditional risk factors? Diabetes Care 2003; 26:2796–803.
20. Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998; 83:2694–8.
21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412–9.
22. Yeni-Komshian H, Carantoni M, Abbasi F, Reaven GM. Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers. Diabetes Care 2000; 23:171–5.
23. Bostom AG, Cupples LA, Jenner JL, Ordovas JM, Seman LJ, Wilson PW, Schaefer EJ, Castelli WP. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger: a prospective study. JAMA 1996; 276:544–8.
24. Marcovina SM, Albers JA, Gabel B, Koschinsky ML, Gaur VP. Effect of number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem 1995; 41:246–55.
25. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40:1387–95.
26. Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, Day C, Arcaro G. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care, 2007; 30:1212–18.
27. Thomas EL, Hamilton G, Patel N, O’Dwyer R, Doré CJ, Goldin RD, Bell JD, Taylor-Robinson SD. Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study. Gut 2005; 54:122–7.
28. Azziz R, Zacur HA. 21-Hydroxylase deficiency in female hyperandrogenism: screening and diagnosis. J Clin Endocrinol Metab 1989; 69:577–84.
29. Azziz R, Dewailly D, Owerbach D. Clinical review 56: nonclassic adrenal hyperplasia: current concepts. J Clin Endocrinol Metab 1994; 78:810–5.
30. Dewailly D. ACTH stimulation tests in women with hirsutism. N Engl J Med 1991 21; 324:564–5.
31. Eldar-Geva T, Hurwitz A, Vecsei P, Palti Z, Milwidsky A, Rosler A. Secondary biosynthetic defects in women with late-onset congenital adrenal hyperplasia. N Engl J Med 1990; 323:855–63.
32. Erel CT, Senturk LM, Oral E, Mutlu H, Colgar U, Seyisoglu H, Ertungealp E. Results of the ACTH stimulation test in hirsute women. J Reprod Med 1999; 44:247–52.
33. LWPES/ESPE (Joint Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology). Congenital Adrenal Hyperplasia Working Group consensus statement on 21-hydroxylase deficiency from the LWPES/ESPE. J Clin Endocrinol Metab 2002; 87:4048–53.
34. Lutfallah C, Wang W, Mason JI, Chang YT, Haider A, Rich B, Castro-Magana M, Copeland KC, David R, Pang S. Newly proposed hormonal criteria via genotypic proof for type II 3beta-hydroxysteroid dehydrogenase deficiency. J Clin Endocrinol Metab 2002; 87:2611–22.
35. Merke DP, Chrousos GP, Eisenhofer G, Weise M, Keil MF, Rogol AD, Van Wyk JJ, Bornstein SR. Adrenomedullary dysplasia and hypofunction in patients with classic 21-hydroxylase deficiency. N Engl J Med 2000; 343:1362–8.
36. Morris AH, Reiter EO, Geffner ME, Lippe BM, Itami RM, Mayes DM. Absence of nonclassical congenital adrenal hyperplasia in patients with precocious adrenarche. J Clin Endocrinol Metab 1989; 69:709–15.
37. New MI, Lorenzen F, Lerner AJ, Kohn B, Oberfield SE, Pollack MS, Dupont B, Stoner E, Levy DJ, Pang S, Levine LS. Genotyping steroid 21-hydroxylase deficiency: hormonal reference data. J Clin Endocrinol Metab 1983; 57:320–6.
38. Siegel SF, Finegold DN, Lanes R, Lee PA. ACTH stimulation tests and plasma dehydroepiandrosterone sulfate levels in women with hirsutism. N Engl J Med 1990; 323:849–54.
39. Speiser, PW, Brenner D. Congenital adrenal hyperplasia resulting from 21-hydroxylase deficiency. Endocrinologist 2003; 13:334–40.
40. Speiser PW, White PC. Congenital adrenal hyperplasia. N Engl J Med 2003; 349:776–88.
41. Speiser PW, Agdere L, Ueshiba H, White PC, New MI. Aldosterone synthesis in salt-wasting congenital adrenal hyperplasia with complete absence of adrenal 21-hydroxylase. N Engl J Med 1991; 324:145–9.
42. Allie S, Rodgers A. Effects of calcium carbonate, magnesium oxide and sodium citrate bicarbonate health supplements on the urinary risk factors for kidney stone formation. Clin Chem Lab Med 2003; 41:39–45.
43. Christmas KG, Gower LB, Khan SR, El-Shall H. Aggregation and dispersion characteristics of calcium oxalate monohydrate: effect of urinary species. J Colloid Interface Sci 2002; 256:168–74.
44. Curhan GC, Willett WC, Speizer FE, Stampfer MJ. Twenty-four-hour urine chemistries and the risk of kidney stones among women and men. Kidney Int 2001; 59:2290–8.
45. Kamel KS, Cheema-Dhadli S, Shafiee MA, Davids MR, Halperin ML. Recurrent uric acid stones. QJM 2005; 98:57–68.
46. Sakhaee K, Poindexter JR, Griffith CS, Pak CY. Stone forming risk of calcium citrate supplementation in healthy postmenopausal women. J Urol 2004; 172:958–61.
47. Schwille PO, Schmiedl A, Manoharan M. Is calcium oxalate nucleation in postprandial urine of males with idiopathic recurrent calcium urolithiasis related to calcium phosphate nucleation and the intensity of stone formation? Studies allowing insight into a possible role of urinary free citrate and protein. Clin Chem Lab Med 2004; 42:283–93.
48. Siener R, Hesse A. The effect of different diets on urine composition and the risk of calcium oxalate crystallisation in healthy subjects. Eur Urol 2002; 42:289–96.
49. Weinstein DA, Somers MJ, Wolfsdorf JI. Decreased urinary citrate excretion in type 1a glycogen storage disease. J Pediatr 2001; 138:378–82.
50. White MP, Aladangady N, Rolton HA, McColl JH, Beattie J. Urinary citrate in preterm and term babies. Early Hum Dev 2005; 81:319–23.
51. Bertelloni S, Federico G, Baroncelli GI, Cavallo L, Corsello G, Liotta A, Rigon F, Saggese G. Biochemical selection of prepubertal patients with androgen insensitivity syndrome by sex hormone-binding globulin response to the human chorionic gonadotropin test. Pediatr Res 1997; 41:266–71.
52. Krause A, Sinnecker GH, Hiort O, Thamm B, Hoepffner W. Applicability of the SHBG androgen sensitivity test in the differential diagnosis of 46, XY gonadal dysgenesis, true hermaphroditism, and androgen insensitivity syndrome. Exp Clin Endocrinol Diabetes 2004; 112:236–40.
53. Sinnecker GH, Hiort O, Nitsche EM, Holterhus PM, Kruse K. Functional assessment and clinical classification of androgen sensitivity in patients with mutations of the androgen receptor gene: German Collaborative Intersex Study Group. Eur J Pediatr 1997; 156:7–14.
54. Bonilla-Musoles F, Ballester MJ, Marti MC, Raga F, Osborne NG. Transvaginal color Doppler assessment of endometrial status in normal postmenopausal women: the effect of hormone replacement therapy. J Ultrasound Med 1995; 14:503–7.
55. Bourne TH, Campbell S, Steer CV, Royston P, Whitehead MI, Collins WP. Detection of endometrial cancer by transvaginal ultrasonography with color flow imaging and blood flow analysis: a preliminary report. Gynecol Oncol 1991; 40:253–9.
56. Van den Bosch T, Vandendael A, Van Schoubroeck D, Wranz PA, Lombard CJ. Combining vaginal ultrasonography and office endometrial sampling in the diagnosis of endometrial disease in postmenopausal women. Obstet Gynecol 1995; 85:349–52.
57. Bajetta E, Ferrari L, Martinetti A, Celio L, Procopio G, Artale S, Zilembo N, Di Bartolomeo M, Seregni E, Bombardieri E. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer 1999; 86:858–65.
58. Barakat MT, Meeran K, Bloom SR. Neuroendocrine tumours. Endocr Relat Cancer 2004; 11:1–18.
59. Deftos LJ. Chromogranin A: Its role in endocrine function and as an endocrine and neuroendocrine tumor marker. Endocr Rev 1991; 12:181–7.
60. Hagn C, Schmid KW, Fischer–Colbrie R, Winkler H. Chromogranin A, B, and C in human adrenal medulla and endocrine tissues. Lab Investig 1986; 55:405–11.
61. Haller DG. Endocrine tumors of the gastrointestinal tract. Curr Opin Oncol 1994; 6:72–6.
62. Hsiao RJ, Parmer RJ, Takiyyuddin MA, O’Connor DT. Chromogranin A storage and secretion: sensitivity and specificity for the diagnosis of pheochromocytoma. Medicine (Baltimore) 1991; 70:33–45.
63. Lamberts SW, Hofland LJ, Nobels FR. Neuroendocrine tumor markers. Front Neuroendocrinol 2001; 22:309–10.
64. Mansour JC, Chen H. Pancreatic endocrine tumors. J Surg Res 2004; 120:139–61.
65. Nobels FR, Kwekkeboom DJ, Bouillon R, Lamberts SW. Chromogranin A: its clinical value as marker of neuroendocrine tumours. Eur J Clin Invest 1998; 28:431–40.
66. Schurmann G, Raeth U, Wiedenmann B, Buhr H, Herfarth C. Serum chromogranin A in the diagnosis and follow-up of neuroendocrine tumors of the gastroenteropancreatic tract. World J Surg 1992:16:697–701.
67. Taupenot L, Harper KL, O’Connor DT. The chromogranin-secretogranin family. N Engl J Med 2003; 348:1134–49.
68. Tomassetti P, Migliori M, Simoni P, Casadei R, De Iasio R, Corinaldesi R., Gullo L. Diagnostic value of plasma chromogranin A in neuroendocrine tumours. Eur J Gastroenterol Hepatol 2001; 13:55–8.
69. Tricoli JV, Schoenfeldt M, Conley BA. Detection of prostate cancer and predicting progression: current and future diagnostic markers. Clin Cancer Res 2004; 10:3943–53.
70. Alaedini A, Green PH. Narrative review: celiac disease—understanding a complex autoimmune disorder. Ann Intern Med 2005; 142:289–98.
71. Farrell RJ, Kelly CP. Diagnosis of celiac sprue. Am J Gastroenterol 2001; 96:3237–46.
72. Hadithi M, von Blomberg BME, Crusius JBA, Bloemena E, Kostense PJ, Meijer JWR, Mulder CJJ, Stehouwer CDA, Peña AS. Accuracy of serologic tests and HLA-DQ typing for diagnosing celiac disease. Ann Intern Med 2007; 147:294–302.
73. Horvath K, Hill ID. Anti-tissue transglutaminase antibody as the first line screening for celiac disease: goodbye antigliadin tests? Am J Gastroenterol 2002; 97:2702–4.
74. Khandwala KM, Chibbar R, Worobetz LJ. A case of celiac disease presenting with malabsorption of L-thyroxine. Endocrinologist 2005; 15:14–17.
75. Levine A, Bujanover Y, Reif S, Gass S, Vardinon N, Reifen R, Lehmann D. Comparison of assays for antiendomysial and anti-transglutaminase antibodies for diagnosis of pediatric celiac disease. Isr Med Assoc J 2000; 2:122–5.
76. Pengiran Tengah CD, Lock RJ, Unsworth DJ, Wills AJ. Multiple sclerosis and occult gluten sensitivity. Neurology 2004; 62:2326–7.
77. Anderson GM, Young JG, Cohen DJ, Schlicht KR, Patel N. Liquid-chromatographic determination of serotonin and tryptophan in whole blood and plasma. Clin Chem 1981; 27:775–6.
78. Kema IP, de Vries EG, Schellings AM, Postmus PE, Muskiet FA. Improved diagnosis of carcinoid tumors by measurement of platelet serotonin. Clin Chem 1992; 38:534–40.